The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I study of 131I-MIBG with dinutuximab for patients with relapsed or refractory neuroblastoma: A report from the new approaches to neuroblastoma therapy (NANT) consortium.
 
Thomas Cash
Honoraria - EUSA Pharma
Consulting or Advisory Role - Y-mAbs Therapeutics
Research Funding - Celgene; Roche/Genentech (Inst)
(OPTIONAL) Uncompensated Relationships - Lilly; United Therapeutics
 
Araz Marachelian
Research Funding - Pfizer (Inst); United Therapeutics (Inst)
 
Steven G. DuBois
Consulting or Advisory Role - Amgen; Bayer
Research Funding - Bayer (Inst); BMS (Inst); Curis (Inst); Eisai (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst); Salarius Pharmaceuticals (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - Roche/Genentech; Salarius Pharmaceuticals
(OPTIONAL) Uncompensated Relationships - Ymabs Therapeutics Inc
 
Yueh-Yun Chi
No Relationships to Disclose
 
Susan G. Groshen
No Relationships to Disclose
 
Anasheh Shamirian
No Relationships to Disclose
 
Alina C Stout
No Relationships to Disclose
 
Margaret E Macy
Stock and Other Ownership Interests - GE Healthcare; Johnson & Johnson; Varian Medical Systems
Consulting or Advisory Role - Ymabs Therapeutics Inc
Research Funding - Abbvie (Inst); Actuate Therapeutics (Inst); Bayer (Inst); Ignyta (Inst); Jubilant DraxImage (Inst); Lilly (Inst); Merck (Inst); Oncternal Therapeutics, Inc (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Patent for non-invasive methods of leukemia cell detection with MRI/MRS - Patent No. 8894975
 
Navin R. Pinto
No Relationships to Disclose
 
Ami Vijay Desai
Stock and Other Ownership Interests - Pfizer; Viatris
Consulting or Advisory Role - Ology Medical Education; Ymabs Therapeutics Inc
Research Funding - Actuate Therapeutics (Inst); GlaxoSmithKline (Inst); Jubilant DraxImage (Inst); Lilly (Inst); Merck (Inst); Roche (Inst); Ymabs Therapeutics Inc (Inst)
 
Paul M. Sondel
Research Funding - Invenra (Inst)
Patents, Royalties, Other Intellectual Property - I am an unpaid medical advisor to Invenra Inc. a monoclonal antibody biotech firm in Madison WI. My UW lab is collaborating with Invenra and receiving research reagents from them for mutual research. (Inst); I have partial interest in patents related to my work at the University of Wisconsin-Madison WI, that are held by and managed by the University of Wisconsin Foundation
(OPTIONAL) Uncompensated Relationships - Invenra
 
Shahab Asgharzadeh
No Relationships to Disclose
 
Brian D. Weiss
Research Funding - Exelixis (Inst); Genentech (Inst); Genentech (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Exelixis; Roche
 
Yael P. Mosse
Consulting or Advisory Role - ASCO; Auron Therapeutics; Jumo Health; Lilly; Pfizer
Research Funding - Pfizer
 
Katherine K. Matthay
Consulting or Advisory Role - Innervate RAdiopharmaceuticals; Resonance
 
Julie R. Park
No Relationships to Disclose
 
Kelly C. Goldsmith
No Relationships to Disclose